Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ablynx, a biopharmaceutical company, has reacquired global rights from Pfizer to develop and commercialise Nanobodies targeting TNF-alpha.
Subscribe to our email newsletter
The rights include ATN-103 and PF-05230905 products.
Ablynx will also acquire Pfizer intellectual property and know-how with regarding to the anti-TNF-alpha programmes and will have access to Pfizer’s current trial supplies of ATN-103 and PF-05230905, assay methods and manufacturing processes.
Pfizer will receive milestone payments valued at $50 million and royalty on sales from Ablynx following the regulatory approval of the first anti-TNF-alpha Nanobody.
In 2006 Ablynx granted Wyeth (acquired by Pfizer in 2009) exclusive worldwide rights to Nanobodies targeting TNF-alpha under a research collaboration and license agreement.